Translational medicine and neurogenetics
The department of Translational Medicine and Neurogenetics brings together 8 research groups. The main unifying theme of the department is the development of integrated approaches for the understanding of major aspects of brain and muscle physiology, with a particular interest in pathophysiological conditions. These include neurodevelopmental, neurobehavioural and neurodegenerative diseases as well as in myopathies (skeletal and cardiac muscle). One of the strengths of the department is the capacity to understand and study the pathophysiology from the genetic and molecular level to the whole living animal. We wish to further develop this integrated axis by including various appropriate omics-data, phenome analysis and in particular live imaging, to obtain an integrated view of the disease process in a living animal over time. Another strength of the department is the translational axis, from the identification of genes implicated in genetics disorders (mostly monogenetic disorders) and development of innovative diagnostic tools (essential link with the diagnostic lab in the hospital), to the development of adequate models of the disease (cell, zebrafish, mouse and rat) that are essential to understand the pathophysiology of the disease and to validate therapeutic approaches, either within the department or in close collaboration with pharmaceutical industries or clinicians.
Four major research activities of the department are 1) the identification of genes involved in monogenic diseases (myopathies, ataxia, intellectual disabilities, cortical malformations and epilepsy) and the development of diagnostic tools, 2) the analysis and modeling of genetic diseases affecting the nervous system or skeletal muscle, 3) the integrative approaches for the analysis of complex brain functions and their dysfunctions relevant to neurological and psychiatric diseases and 4) the development and validation of therapeutic strategies.
The Department has strong links to the Faculty of Medicine, the Strasbourg Academic Hospital (CHU), and with the Institut Clinique de la Souris, and strong cooperations with clinicians, patients associations and the pharmaceutical industry.